GRI Bio, Inc.
GRIDrugs in Pipeline
1
Phase 3 Programs
0
Upcoming Catalysts
1
Next Catalyst
Next month
Market Overview
Stock performance and key metrics
1 upcoming, 0 past
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Tazarotene (GRI-0621) | Phase 2 | Idiopathic Pulmonary Fibrosis | - | - |
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in GRI Bio, Inc.'s drug pipeline?→
CatalystAlert tracks 1 drug candidate in GRI Bio, Inc.'s (GRI) pipeline across Phase 2. Its lead program is Tazarotene (GRI-0621) (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is GRI Bio, Inc.'s next FDA catalyst?→
GRI Bio, Inc.'s (GRI) next tracked catalyst is a Earnings expected November 13, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track GRI biotech catalysts?→
Add GRI to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow GRI Bio, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.